Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens.

Rodrigues CMC, Chan H, Vipond C, Jolley K, Harrison OB, Wheeler J, Whiting G, Feavers IM, Maiden MCJ.

Version 2. Wellcome Open Res. 2019 Mar 19 [revised 2019 Jan 1];3:151. doi: 10.12688/wellcomeopenres.14859.2. eCollection 2018.

2.

Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines.

Beresford NJ, Martino A, Feavers IM, Corbel MJ, Bai X, Borrow R, Bolgiano B.

Vaccine. 2017 Jun 16;35(28):3598-3606. doi: 10.1016/j.vaccine.2017.03.066. Epub 2017 Apr 10.

3.

Recent Progress in the Prevention of Serogroup B Meningococcal Disease.

Feavers IM, Maiden MCJ.

Clin Vaccine Immunol. 2017 May 5;24(5). pii: e00566-16. doi: 10.1128/CVI.00566-16. Print 2017 May. Review.

4.

Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".

Wetzler LM, Feavers IM, Gray-Owen SD, Jerse AE, Rice PA, Deal CD.

Clin Vaccine Immunol. 2016 Aug 5;23(8):656-63. doi: 10.1128/CVI.00230-16. Print 2016 Aug. Review.

5.

Dissection of the function of the RmpM periplasmic protein from Neisseria meningitidis.

Maharjan S, Saleem M, Feavers IM, Wheeler JX, Care R, Derrick JP.

Microbiology. 2016 Feb;162(2):364-375. doi: 10.1099/mic.0.000227. Epub 2015 Dec 16.

PMID:
26678687
6.

FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression.

Sanders H, Norheim G, Chan H, Dold C, Vipond C, Derrick JP, Pollard AJ, Maiden MC, Feavers IM.

PLoS One. 2015 Oct 14;10(10):e0140345. doi: 10.1371/journal.pone.0140345. eCollection 2015.

7.

A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.

Marsay L, Dold C, Green CA, Rollier CS, Norheim G, Sadarangani M, Shanyinde M, Brehony C, Thompson AJ, Sanders H, Chan H, Haworth K, Derrick JP, Feavers IM, Maiden MC, Pollard AJ.

J Infect. 2015 Sep;71(3):326-37. doi: 10.1016/j.jinf.2015.05.006. Epub 2015 May 15.

8.

Identification of vaccine antigens using integrated proteomic analyses of surface immunogens from serogroup B Neisseria meningitidis.

Tsolakos N, Brookes C, Taylor S, Gorringe A, Tang CM, Feavers IM, Wheeler JX.

J Proteomics. 2014 Apr 14;101:63-76. doi: 10.1016/j.jprot.2014.02.013. Epub 2014 Feb 21.

PMID:
24561796
9.

The distribution and 'in vivo' phase variation status of haemoglobin receptors in invasive meningococcal serogroup B disease: genotypic and phenotypic analysis.

Lucidarme J, Findlow J, Chan H, Feavers IM, Gray SJ, Kaczmarski EB, Parkhill J, Bai X, Borrow R, Bayliss CD.

PLoS One. 2013 Sep 30;8(9):e76932. doi: 10.1371/journal.pone.0076932. eCollection 2013.

10.

Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis.

Saleem M, Prince SM, Rigby SE, Imran M, Patel H, Chan H, Sanders H, Maiden MC, Feavers IM, Derrick JP.

PLoS One. 2013;8(2):e56746. doi: 10.1371/journal.pone.0056746. Epub 2013 Feb 15.

11.

Resolution of a meningococcal disease outbreak from whole-genome sequence data with rapid Web-based analysis methods.

Jolley KA, Hill DM, Bratcher HB, Harrison OB, Feavers IM, Parkhill J, Maiden MC.

J Clin Microbiol. 2012 Sep;50(9):3046-53. doi: 10.1128/JCM.01312-12. Epub 2012 Jul 11.

12.

History of meningococcal vaccines and their serological correlates of protection.

Vipond C, Care R, Feavers IM.

Vaccine. 2012 May 30;30 Suppl 2:B10-7. doi: 10.1016/j.vaccine.2011.12.060. Review.

PMID:
22607894
13.

Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis.

Saleem M, Prince SM, Patel H, Chan H, Feavers IM, Derrick JP.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Feb 1;68(Pt 2):231-5. doi: 10.1107/S1744309111056028. Epub 2012 Jan 27.

14.

The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes.

Sanders H, Brehony C, Maiden MC, Vipond C, Feavers IM.

Microbiology. 2012 Apr;158(Pt 4):869-76. doi: 10.1099/mic.0.054957-0. Epub 2012 Jan 12.

15.

Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: an investigational vaccine component against Neisseria meningitidis.

Martino A, Magagnoli C, De Conciliis G, D'Ascenzi S, Forster MJ, Allen L, Brookes C, Taylor S, Bai X, Findlow J, Feavers IM, Rodger A, Bolgiano B.

Vaccine. 2012 Feb 8;30(7):1330-42. doi: 10.1016/j.vaccine.2011.12.066. Epub 2011 Dec 27.

PMID:
22210226
16.

Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.

Sanders H, Feavers IM.

Expert Rev Vaccines. 2011 Mar;10(3):323-34. doi: 10.1586/erv.11.10. Review.

PMID:
21434800
17.

Influence of the combination and phase variation status of the haemoglobin receptors HmbR and HpuAB on meningococcal virulence.

Tauseef I, Harrison OB, Wooldridge KG, Feavers IM, Neal KR, Gray SJ, Kriz P, Turner DP, Ala'Aldeen DA, Maiden MC, Bayliss CD.

Microbiology. 2011 May;157(Pt 5):1446-56. doi: 10.1099/mic.0.046946-0. Epub 2011 Feb 10.

18.

Variation in the Neisseria meningitidis FadL-like protein: an evolutionary model for a relatively low-abundance surface antigen.

Yero D, Vipond C, Climent Y, Sardiñas G, Feavers IM, Pajón R.

Microbiology. 2010 Dec;156(Pt 12):3596-608. doi: 10.1099/mic.0.043182-0. Epub 2010 Sep 3. Erratum in: Microbiology. 2011 Feb;157(Pt 2):616.

PMID:
20817647
19.

Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media.

Tsolakos N, Lie K, Bolstad K, Maslen S, Kristiansen PA, Høiby EA, Wallington A, Vipond C, Skehel M, Tang CM, Feavers IM, Wedege E, Wheeler JX.

Vaccine. 2010 Apr 19;28(18):3211-8. doi: 10.1016/j.vaccine.2010.02.023. Epub 2010 Feb 25.

PMID:
20188677
20.

Variation and molecular evolution of HmbR, the Neisseria meningitidis haemoglobin receptor.

Evans NJ, Harrison OB, Clow K, Derrick JP, Feavers IM, Maiden MC.

Microbiology. 2010 May;156(Pt 5):1384-93. doi: 10.1099/mic.0.036475-0. Epub 2010 Feb 11.

21.

Meningococcal protein antigens and vaccines.

Feavers IM, Pizza M.

Vaccine. 2009 Jun 24;27 Suppl 2:B42-50. doi: 10.1016/j.vaccine.2009.05.001. Epub 2009 May 28. Review.

PMID:
19481315
22.

Epidemiological evidence for the role of the hemoglobin receptor, hmbR, in meningococcal virulence.

Harrison OB, Evans NJ, Blair JM, Grimes HS, Tinsley CR, Nassif X, Kriz P, Ure R, Gray SJ, Derrick JP, Maiden MC, Feavers IM.

J Infect Dis. 2009 Jul 1;200(1):94-8. doi: 10.1086/599377.

23.

Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines.

Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MC.

Microbiology. 2008 Apr;154(Pt 4):1170-7. doi: 10.1099/mic.0.2007/014761-0.

24.

Species status of Neisseria gonorrhoeae: evolutionary and epidemiological inferences from multilocus sequence typing.

Bennett JS, Jolley KA, Sparling PF, Saunders NJ, Hart CA, Feavers IM, Maiden MC.

BMC Biol. 2007 Sep 7;5:35.

25.

Exploring the proteome of meningococcal outer membrane vesicle vaccines.

Wheeler JX, Vipond C, Feavers IM.

Proteomics Clin Appl. 2007 Sep;1(9):1198-210. doi: 10.1002/prca.200700204. Epub 2007 Aug 17.

PMID:
21136768
26.

Role of bacterial endotoxin in chronic heart failure: the gut of the matter.

Charalambous BM, Stephens RC, Feavers IM, Montgomery HE.

Shock. 2007 Jul;28(1):15-23. Review.

PMID:
17510602
27.

Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry.

Vipond C, Wheeler JX, Jones C, Feavers IM, Suker J.

Hum Vaccin. 2005 Mar-Apr;1(2):80-4. Epub 2005 Mar 2.

PMID:
17038831
28.

Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.

Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX.

Proteomics. 2006 Jun;6(11):3400-13. Erratum in: Proteomics. 2006 Jul;6(14):4203.

PMID:
16645985
29.

Structural variation and immune recognition of the P1.2 subtype meningococcal antigen.

Tzitzilonis C, Prince SM, Collins RF, Achtman M, Feavers IM, Maiden MC, Derrick JP.

Proteins. 2006 Mar 1;62(4):947-55.

PMID:
16470851
30.

The immunogenicity of a conformationally restricted peptide mimetic of meningococcal lipooligosaccharide.

Tiwana H, Clow KJ, Hall C, Feavers IM, Charalambous BM.

Scand J Immunol. 2005 Oct;62(4):385-92.

31.

Control and lot release of meningococcal group C conjugate vaccines.

Suker J, Feavers IM, Corbel MJ, Jones C, Bolgiano B.

Expert Rev Vaccines. 2004 Oct;3(5):533-40. Review.

PMID:
15485333
32.

Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.

Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden MC.

Infect Immun. 2004 Oct;72(10):5955-62.

33.

PorA variable regions of Neisseria meningitidis.

Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J.

Emerg Infect Dis. 2004 Apr;10(4):674-8.

34.
35.

Optimization of nb-4 and hl-60 differentiation for use in opsonophagocytosis assays.

Fleck RA, Athwal H, Bygraves JA, Hockley DJ, Feavers IM, Stacey GN.

In Vitro Cell Dev Biol Anim. 2003 May-Jun;39(5-6):235-42.

PMID:
12873158
36.

Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component.

Thompson EA, Feavers IM, Maiden MC.

Microbiology. 2003 Jul;149(Pt 7):1849-58.

PMID:
12855736
37.
38.

Neisseria lactamica protects against experimental meningococcal infection.

Oliver KJ, Reddin KM, Bracegirdle P, Hudson MJ, Borrow R, Feavers IM, Robinson A, Cartwright K, Gorringe AR.

Infect Immun. 2002 Jul;70(7):3621-6.

39.

Development of vaccines against meningococcal disease.

Jódar L, Feavers IM, Salisbury D, Granoff DM.

Lancet. 2002 Apr 27;359(9316):1499-508. Review.

PMID:
11988262
41.

Mimotope vaccines.

Charalambous BM, Feavers IM.

J Med Microbiol. 2001 Nov;50(11):937-9. No abstract available.

PMID:
11699588
42.

Prospects offered by genome studies for combating meningococcal disease by vaccination.

Suker J, Feavers IM.

Pharmacogenomics. 2001 Aug;2(3):273-83. Review.

PMID:
11535115
43.

Localization of GerAA and GerAC germination proteins in the Bacillus subtilis spore.

Hudson KD, Corfe BM, Kemp EH, Feavers IM, Coote PJ, Moir A.

J Bacteriol. 2001 Jul;183(14):4317-22.

45.

Identification of Peptides that Mimic N. meningitidis LOS Epitopes Via the Use of Combinatorial Phage-Display Libraries.

Brett PJ, Feavers IM, Charalambous BM.

Methods Mol Med. 2001;66:181-97. doi: 10.1385/1-59259-148-5:181.

PMID:
21336756
46.

Meningococcal vaccines and vaccine developments.

Feavers IM.

Methods Mol Med. 2001;66:1-22. doi: 10.1385/1-59259-148-5:1.

PMID:
21336743
47.

Meningococcal genomics: two steps forward, one step back.

Maiden MC, Feavers IM.

Nat Med. 2000 Nov;6(11):1215-6. No abstract available.

PMID:
11062528
48.
49.

Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.

Jodar L, Cartwright K, Feavers IM.

Biologicals. 2000 Sep;28(3):193-7. Review. No abstract available.

PMID:
10964447
50.

ABC of meningococcal diversity.

Feavers IM.

Nature. 2000 Mar 30;404(6777):451-2. No abstract available.

PMID:
10761900

Supplemental Content

Loading ...
Support Center